Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: J Clin Pharmacol. 2014 Aug 22;55(1):39–44. doi: 10.1002/jcph.372

Figure 3. Rilonacept systemic exposure vs. response.

Figure 3

Rilonacept response at 12 weeks is defined as a composite of improvement in the American College of Rheumatology Pediatric 30 (ACR Pedi 30) criteria, the absence of fever ≥38.5ºC in the previous 2 weeks, and at least 10% taper in the dose of systemic corticosteroids from baseline in patients receiving corticosteroids.

AUC0-inf indicates area under the concentration time curve from 0 to infinity.